Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405758 | 0.88 | KMT2A (0.41) | KMT2ACHRM1MEN1NPC1RAB9A | |
| SCHEMBL2408117 | 0.81 | KMT2A (0.52) | KMT2ACHRM1NPC1ALDH1A1CCR5 | |
| SCHEMBL27500492 | 0.80 | TAAR1 (0.44) | KMT2ACHRM1MEN1NPC1RAB9A | |
| SCHEMBL2407533 | 0.78 | KCNH2 (0.49) | KMT2AMEN1NPC1RAB9ACCR5 | |
| SCHEMBL2406603 | 0.77 | HTR2A (0.47) | KMT2ACHRM1MEN1RAB9ANPSR1 | |
| SCHEMBL15297065 | 0.77 | GRM1 (0.36) | KMT2AMEN1SMN1; SMN2TAAR1 | |
| SCHEMBL2403274 | 0.77 | ICMT (0.49) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2404555 | 0.77 | CCR5 (0.44) | KMT2AMEN1RAB9AALDH1A1CCR5 | |
| SCHEMBL2404441 | 0.76 | NPC1 (0.52) | KMT2ANPC1CCR5POLB | |
| SCHEMBL37138 | 0.71 | SRC (0.58) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | KMT2A 253/4885CHRM1 152/4885MEN1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.